Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane®) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia

Pascalina Chanda*, Moonga Hawela, Mabvuto Kango and Naawa Sipilanyambe

Address: National Malaria Control Centre, P.O. Box 32509, Lusaka, Zambia

Email: Pascalina Chanda* - pasychanda@mailcity.com; Moonga Hawela - mhawela@nmcc.org.zm; Mabvuto Kango - mkango@nmcc.org.zm; Naawa Sipilanyambe - malaria@nmcc.org.zm

* Corresponding author

Abstract

Background: Sentinel site surveillance of antimalarials by in-vivo therapeutic efficacy studies in Zambia is one of the key activities ear-marked for monitoring and evaluation. The studies are conducted annually in order to provide timely and reliable information on the status of the recommended regimens for malaria case management. The findings of the therapeutic efficacy of an artemisinin-based combination therapy of pediatric artemether-lumefantrine (Coartesiane®) are reported.

Method: The design is a simple, one-arm, prospective evaluation of the clinical and parasitological response to directly observed treatment for uncomplicated malaria. The study was conducted in sentinel sites using the WHO standardized protocol for the assessment of therapeutic efficacy of antimalarial drugs (WHO 2000) in children under five years of age, weighing less than 10 Kg. The study was conducted at two clinics, one in Chongwe (Lusaka Province) and Chipata (Eastern Province). The 28-day follow-up period was used coupled with PCR genotyping for MSP1 and MSP2 in order to differentiate recrudescence from re-infections for parasites that appeared after Day 14.

Results: 91/111 children enrolled in the study, were successfully followed up. Artemether-lumefantrine (Coartesiane®) was found to produce significant gametocyte reduction. The Adequate Clinical and Parasitological Response (ACPR) was found to be 100% (95% CI 96.0;100).

Conclusion: Coartesiane® was effective in treating uncomplicated malaria in Zambian children weighing less than 10 kg, an age group normally excluded from taking the tablet formulation of artemether-lumefantrine (Coartem®).

Background

The malaria situation analysis in Zambia shows that malaria is the leading cause of mortality and morbidity, and the disease burden is worse in the biologically vulner-
to chloroquine and sulphadoxine/pyrimethamine (SP), with recorded treatment failures for SP as high as 32.6% in certain parts of the country by early 2003 [2]. After the documentation of chloroquine resistance in 1983, the outpatient department (OPD) cases increased from 167 cases per thousand population to 428 cases per thousand population in 2003 [3]. The public health impact of drug resistance led to an increase in the disease prevalence rates, under five mortality rates and a corresponding increase in case fatality rates. This was evidenced by an upward surge in all epidemiological indicators of the malaria disease.

The assessment and monitoring of antimalarial therapeutic efficacy is key to the provision of sound evidence for policy decisions making regarding which antimalarials can be adopted for malaria case management. The National Malaria Control Centre has over time developed a consistent system for sentinel site surveillance of the therapeutic efficacy of antimalarial drugs. These studies have played a major role in guiding the country’s decision to move from monotherapies to Artemisinin-Based Combination Therapies (ACTs).

The use of combination therapy is expected to have a positive impact on malaria transmission by lowering the rates of gametocytaemia after treatment. Artemisinin derivatives are advocated for use in antimalarial combination therapy because they quickly reduce the level of parasitaemia and hence the parasite pool from which resistant P. falciparum strains may arise [4].

But, as the new drug policy outlines, SP is the current recommended drug for intermittent presumptive treatment for malaria in pregnancy and for children weighing less than 10 Kg. These two groups were excluded from using the tablet formulation of artemether-lumefantrine (Coartem®), because there was insufficient safety and efficacy data at the time of the policy change.

The therapeutic efficacy of Coartesiane® in treating uncomplicated Plasmodium falciparum malaria in children was assessed. The findings will be useful in providing evidence on the possible options for children who currently are being exposed to the ineffective SP.

**Study population and sample size**

The patients included were children under five years of age, weighing less than 10 Kg (the minimum weight admissible for Coartem®). Other criteria used for inclusion were: absence of severe malnutrition, mono-infection with P. falciparum, with a parasitaemia in the range of 2,000 to 200,000 asexual parasites per micro litre of blood, absence of severe malaria or danger signs, axillary temperature ≥ 37.5°C at visit, absence of other febrile conditions, ability to come for follow-up visit and informed consent from parent or guardian.

The classical statistical methods for determining sample size based on an expected proportion of treatment failures was used, with a 95% confidence level and a precision of 10%. The failure rates were expected to be lower than 15%, so a minimum of 50 patients had to be enrolled at each site.

**Parasitological examination**

Two thick films were prepared before treatment on Day 0, and on Days 1, 2, 3, 7, 14, 21 and 28 including any other day that the patient was brought to the clinic before the next scheduled visit. One thick film was used for rapid staining (10–15 minutes in 10% Giemsa stain) while the second film was for slow staining (30–45 minutes in 3% Giemsa stain). The quick stain was used for initial screening for the presence of parasites, while the second blood smear was used to calculate parasite density. Parasitaemia (per microlitre) = number of parasites × 8,000/number of leucocytes counted.

Two laboratory technicians were engaged in the study and both read through all the slides independently to assure quality. All the slides for the patients on the study were collected and used in quality control by an independent laboratory.

**Treatment and follow-up**

The study followed the standard World Health Organization (WHO) Protocol for the Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Plasmodium falciparum malaria adapted to the Zambian situation to include studies with artemisinin-based combination therapy. The 28-day follow-up period was used.

On enrolment day, Day 0, a brief history of each child was obtained, the patient was weighed and the axillary temperature was recorded. The patient was then sent for laboratory examination to confirm malaria diagnosis and also to identify if parasitaemia was adequate for enrolment. Upon fulfillment of all inclusion criteria, consent was obtained from the caretaker and the child was enrolled on the study.
Coartesiane® is an oral suspension of artemether (180 mg/60 ml) and lumefantrine (1080 mg/60 ml) indicated for the treatment of malaria in children. It is presented in a yellow powder which can be diluted with water to form a 60 ml suspension. The dosing schedule is based on body weight and it is to be taken once a day for three days. The drug is manufactured by Dafra Pharma nv/sa. The drug is registered in Zambia for use in children for the treatment of uncomplicated malaria and is being used in the private sector.

All medication was given under the supervision of the study team. Patients were observed for a few minutes after administering the study drug to ensure that they did not vomit. Any child who vomited had the dose re-administered but if vomiting persisted, the child was dropped from the study and referred for further management. A photograph of the child was taken as an identification tool on follow-up days and also as an incentive upon completion of the study.

Follow-ups were scheduled for Days 2, 3, 7, 14, 21 and 28 plus any other day that the child was taken to the clinic on unscheduled day. On each of these days clinical and parasitological assessments were performed. The community health worker ensured the directions to the home of the patient were well written for ease of tracking of patients.

Filter paper samples of blood were taken on Day 0 and any other day when the parasites first reappeared in the blood of the patient. Polymerase Chain Reaction (PCR) genotyping for MSP1 and MSP2 was done to differentiate recrudescence from re-infections. DNA was extracted from the filter papers and analysed using standard methods as described elsewhere [5,6]. A recrudescence infection was defined if the allelic bands of the subsequent infection were similar to the Day 0 pattern. However, a reinfection was defined if the allelic bands for the subsequent infection were different from the Day 0 bands.

Children were withdrawn from the study if the patient developed any signs of severe or complicated malaria or any of the general danger signs during the follow-up period; he/she was given the first dose of parenteral quinine and taken urgently to the appropriate health facility. For ethical reasons, all children with parasitaemia on Day 28, irrespective of symptoms were treated with the alternative antimalarial drug (oral quinine) at the end of the follow-up period.

**Incentives**

Incentives were given to the caretakers as a way to motivate them not to miss a scheduled visit to the study site. A 1 Kg packet of sugar was given to each patient on Day 3, a bar of laundry soap on Day 7 and a packet of salt on Day 14 and a photograph of the child on Day 28. Any child, who dropped from the study before Day 28, received the photo on the last day of being on the study. Sweets were given to the children as an incentive for the number of finger pricks they get on the study.

**Data collection**

The data was recorded depending on the day of the study. The screening Log sheet was kept in the laboratory and this had serial numbers and information of all the patients screened for the study irrespective of their parasitaemia and clinical condition. The Case enrolment form was used for the patient’s case history and it also contained clinical and parasitological data for Day 0. The case record form was used to record the patients’ study number, directions to home, study drug, and all the clinical and parasitological data for Day 0 to Day 28, and the final classification of therapeutic response.

**Classification of therapeutic response**

Three categories of therapeutic response, namely Early Treatment Failure (ETF), Late Treatment Failure (LTF) and Adequate Clinical and Parasitological Response (ACPR) were used. This is based on the WHO classification system [7]. At all times during the study, the patient welfare took priority and all the procedures were done in line with the standard guidelines of good practice.

The statistical procedure adapted for the interpretation of the results allowed testing the hypothesis that the proportion of treatment failures was above a certain level in the study area, and, therefore, a decision to change is deemed necessary.

Collaboration with the major institutions in the country ensured the quality of study results. The study team members came from the National Malaria Control Centre, Tropical Diseases Research Centre, Macha Malaria Research Institute, University Teaching Hospital and Chainama Hills College of Health Sciences and District Health Management teams (DHMTs).

**Ethical considerations**

The study was conducted in accordance with the standards of good clinical practice.

Ethical clearance was sought from The Tropical Disease Research Centre Institutional Research Committee (#00002911). The study was also cleared by the Central Board of Health Director General’s Office and the participating districts. All participants were enrolled after a written consent was obtained from the caretaker. The participants also received incentives to help them during the long follow up days. All information obtained in the study was treated with the confidentiality it deserved.
Results
Out of the 111 patients enrolled in the two sites, 91 were successfully followed up. Baseline characteristics of participants are outlined in Table 1. The ACPR after 28 days follow up was 100% (95% confidence interval 96.0% to 100%). There were no early treatment failures reported and all the analysable LCF and LPF were due to re-infections. The gametocytes that were reported to be present on Day 0 (368 per microlitre of blood) and Day 2 (336 per microlitre of blood) reduced significantly by Day 7 (80/µl of blood), with none being recorded on Day 21 and Day 28. No clinically detectable drug reactions were reported during the study period. The rate of re-infection was found to be 37% (Chongwe) and 20.8% (Chipata), respectively (Table 2).

Discussion
Coartesiane® was found to have excellent 28-day therapeutic efficacy among children weighing less than 10 Kg. This drug has the potential of providing a viable option for children who are not eligible to take Coartem®. There is need, therefore, to continue to evaluate the long-term safety profile of this drug in the younger children. The drug had 28-day ACPR rates superior to those of SP (100% vs 76.1%) being recorded in Zambia in children with similar age and weight characteristics.

The study is limited in nature because it was not a randomized clinical trial which would have been ideal. However, an open label was opted for because there is sufficient data on the efficacy of the tablet formulation of artemether-lumefantrine[8-11].

Further studies are needed to estimate the long-term safety and pharmacological action of this pediatric formulation. This will provide more information for countries where the use of this drug may be contemplated. The gametocyte clearance characteristics were similar to those, which have been recorded with the tablet formulation of artemether-lumefantrine [8,9]. The use of MSP genotyping to differentiate re-infections from recrudescent strains has been useful in evaluating the therapeutic efficacy of the drug.

Conclusion
Coartesiane® was very effective in treating uncomplicated P. falciparum malaria in children weighing less than 10 Kg in Zambia.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
PC was responsible for the proposal development, study design, training of research assistants, data analysis and developing of the manuscript. MH was involved in sampling, training of research assistants, field supervision and revision of the manuscript. MK participated in the writing of the manuscript and case management. NS was involved in supervision and manuscript development.

Acknowledgements
The funding for this study was made available from Global Funds for HIV/AIDS, Tuberculosis, Malaria (GFATM). Thanks to the District Health Management Teams (DHMTs), research assistants and caretakers for participating in the study, and to Dr. P. Thuma of Malaria Institute at Macha (MIAM) and Dr V. Chalwe of Tropical Diseases Research Centre (TDRC) for comments on the earlier manuscript.

Table 1: Baseline characteristics of participants

| Variable               | Chongwe | Chipata |
|------------------------|---------|---------|
| Number Screened        | 326     | 627     |
| Parasite Rates (%)     | 53.7    | 30.8    |
| Number Enrolled        | 54      | 57      |
| Mean age (months)      | 22.3    | 23.5    |
| Female (%)             | 49.08   | 54.6    |
| Mean weight            | 13.7    | 10.9    |
| Mean Temp, Day 0       | 37.7    | 38.7    |

Table 2: Therapeutic response to Co-artesiane®

| Variable               | Chongwe N = 54 | Chipata N = 57 |
|------------------------|----------------|----------------|
| Exclusion              | 0              | 0              |
| Loss to follow-up      | 0              | 0              |
| Withdrawal             | 0              | 0              |
| ETFU                   | 0              | 0              |
| LCFU                   | 8              | 14.8           |
| LPFU                   | 27             | 50             |
| ACPRU                  | 27             | 50             |
| Re-infections          | 20             | 37             |
| LTFC                   | 0              | 0              |
| Inadequate sample      | 7              | 3              |
| Evaluable              | 47             | 44             |
| ACPRC                  | 47             | 100            |

References
1. National Malaria Control Centre: National Malaria Situation Analysis Lusaka, Zambia; 2000.
2. Chanda P, Sikaala C, Kapelwa W, Nkunika S, MacDonald M, Thea DM, MacLeod WB, Sipilanyambe N, Hamer DH: Decreasing efficacy of sulphadoxine-pyrimethamine (SP) in Zambian children. 53rd Annual Meeting of the Society of Tropical Medicine and Hygiene. Miami, FL: Abstract 708
3. Central Board of Health: Annual Health Statistics Bulletin Lusaka, Zambia; 2003.
4. World Health Organization: The use of antimalarial drugs. Report for a WHO informal consultation, 13–17th November 2000. WHO/CDS/RBM/2001/2000, 33:
5. Cattamanchi A, Kyabazinga D, Hubbard A, Rosenthal PJ, Dorsey G: Distinguishing recrudescence from reinfection in a longitudi-
nal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2 and glurp. Am J Trop Med Hyg 2003, 68:133-139.

6. Nzila AM, Mberu EK, Nduati E, Ross A, Watkins WM, Sibley CH: Genetic diversity of Plasmodium falciparum parasites from Kenya is not affected by antifolate drug selection. Int J Parasitol 2002, 32:1469-1476.

7. World Health Organization: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HPTM/RBM/2003 Volume 50. Geneva, World Health Organization; 2003:1-68.

8. Vugt MV, Wilairatana P, Gemperli B, Gathman I, Phaipun L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S. Efficacy of six doses of arteether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999, 60:936-942.

9. Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R: A clinical and pharmacokinetic trial of six doses of artether-lumefantrine for multidrug resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001, 64:247-256.

10. Jima D, Tsefaye G, Medhin A, Kebede A, Argaw D, Babaniyi O: Safety and efficacy of artether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 2005, 82:385-386.

11. Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman A, Thwai KL, Singhasivanon P, Jelinek T, White NJ, Nosten FH: A randomised trial of artether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multidrug resistant Plasmodium falciparum on the Western border of Thailand. Malar J 2005, 4:46.

12. Chanda P, Sikaala CH, Kapelwa W, Moonga H, Njunju E, Macdonald M, Thea D, Hamer DH, Sipilanyambe N: Assessment of the therapeutic efficacy of artether-lumefantrine (Coartem®) and sulphadoxine-pyrimethamine (SP)-artesunate in Zambian children. 53rd Annual Meeting of the Society of Tropical Medicine and Hygiene, 7-11 November 2004, Miami, FL. Abstract 213.